Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03456830 · ClinicalTrials.gov registry record · Phase 3
Evaluate ALLN-177 in Patients With Enteric Hyperoxaluria
A Phase 3 study, sponsored by Allena Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 115
- Enrollment target
NCT03456830: Completed Phase 3 study, sponsored by Allena Pharmaceuticals.
NCT03456830 is a Phase 3 study that has completed, run by Allena Pharmaceuticals. The registered enrollment target is 115 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03456830, a Phase 3 study, has completed, sponsored by Allena Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 115 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the efficacy and safety of ALLN-177 in patients with enteric hyperoxaluria.
Primary Outcome
Efficacy will be assessed based on percent change from baseline to the mean of Weeks 1-4, derived from all 24-hour collections during Weeks 1-4 on treatment
Interventions
- DRUG Placebo
- DRUG ALLN-177
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 115 participants |
| Start Date | 2018-05-21 |
| Est. Completion | 2019-10-28 |
| Phase | Phase 3 |
What the finished NCT03456830 record still lists
NCT03456830 is an interventional study that assigns participants to a tested intervention. The registered 115 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (85% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03456830 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03456830 about?
NCT03456830 is a clinical study titled "Evaluate ALLN-177 in Patients With Enteric Hyperoxaluria". The purpose of this study is to determine the efficacy and safety of ALLN-177 in patients with enteric hyperoxaluria.
What is the current status of trial NCT03456830?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 115 participants. The study started on 2018-05-21. Estimated completion is 2019-10-28.
What interventions are being tested in trial NCT03456830?
The interventions under investigation include: Placebo (DRUG), ALLN-177 (DRUG).
Who is sponsoring clinical trial NCT03456830?
This trial is sponsored by Allena Pharmaceuticals, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03456830's enrollment target sits among peer trials
115 1644th of 2000 higher than 353 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02346929 · 115 participants · NA
Hematoma Block for Distal Radius Fracture
- NCT03394365 · 115 participants · Phase 3
A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
- NCT03907475 · 115 participants · Phase 2
Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial
- NCT05086692 · 115 participants · Phase 1
A Beta-only IL-2 ImmunoTherapY Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI